Login to Your Account



Financings Roundup

Stemline Therapeutics Follows Verastem's Lead, Files for IPO

By Marie Powers
Staff Writer

Wednesday, April 4, 2012
Following the lead of Verastem Inc., which raised $55 million earlier this year in its initial public offering (IPO), New York-based Stemline Therapeutics Inc. filed an S-1 registration statement with the SEC for an IPO, seeking $50 million to advance its cancer stem cell therapeutics.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription